Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 5/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.44 |
| ▸ | KDM6B | O15054 | 2/20 | 0.44 |
| ▸ | KDM5C | P41229 | 2/20 | 0.44 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 11/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7328047 | 0.85 | LMNA (0.46) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL11252438 | 0.83 | EPHX2 (0.50) | LMNA | |
| SCHEMBL1869025 | 0.81 | PHF8 (0.46) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL13804019 | 0.81 | ALDH1A1 (0.47) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL14344729 | 0.80 | PHF8 (0.41) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL12927432 | 0.80 | PHF8 (0.41) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL7942491 | 0.80 | CHRM1 (0.48) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL31370382 | 0.80 | CTH (0.34) | PHF8KDM2AEGLN1KDM6BKDM5C | |
| SCHEMBL13452945 | 0.78 | LMNA (0.43) | PHF8KDM2AKDM7ALMNACHRM1 | |
| SCHEMBL20128392 | 0.78 | KMT2A (0.61) | PHF8KDM2AEGLN1KDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4355350-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022261257-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-2013196-B1 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2013196-B1 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-8785457-B2 | Pyrimidine derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| EP-2013196-A2 | DISUBSTITUTED ANILINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070054981-A1 | Ink set and method and apparatus for recording image | FUJI PHOTO FILM CO., LTD (JP) | 2007-03-08 | — | — | US | disclosed |
| CN-1746255-A | Polishing compound and method for polishing substrate | HITACHI CHEMICAL CO LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
| US-5773530-A | USEFUL AS PSYCHOSTIMULANTS, ANTIHYPERTENSIVE AGENTS AND REMEDIES FOR RENAL FAILURE, DIURETICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PHF8 2519/4885KDM2A 2912/4885EGLN1 2371/4885 |
| US-20090221669-A1 | Disubstituted Aniline Compounds | TXNRD2, BRDT, HDAC1 | PHF8 946/4885KDM2A 375/4885EGLN1 1694/4885 |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | PHF8 2116/4885KDM2A 2813/4885EGLN1 1354/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | PHF8 1528/4885KDM2A 2830/4885EGLN1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.